SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial

Abstract Background SGLT2i exerts several cardiometabolic benefits in heart failure with reduced and preserved ejection fraction through the systemic reduction of insulin, visceral fat, chemokines and growth factors involved in cardiovascular diseases. Anthracyclines are considered the principal cul...

ver descrição completa

Detalhes bibliográficos

Principais autores:	A. Greco, V. Quagliariello, G. Rizzo, A. Tedeschi, S. Schirinzi, A. Turco, M. Galiazzo, M. Acquaro, M. De Amicis, C. Klersy, S. Ghio, L. Perrone, A. Paccone, G. Uccello, M. L. Canale, S. Oliva, F. Guerra, L. De Luca, N. Maurea, L. Scelsi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-09-01
coleção:	Cardio-Oncology
Assuntos:	Cardiovascular disease Risk factors Beast cancer Cardio-oncology Inflammation Metabolism
Acesso em linha:	https://doi.org/10.1186/s40959-025-00368-9
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!